Ovid Therapeutics (OVID) Net Cash Flow Growth (5y) (2021 - 2026)
Ovid Therapeutics (OVID) Net Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.83% |
| Dec 31, 2025 | 13.32% |
| Sep 30, 2025 | -16.76% |
| Jun 30, 2025 | -12.27% |
| Mar 31, 2025 | 18.72% |
| Dec 31, 2024 | 23.12% |
| Sep 30, 2024 | -9.20% |
| Jun 30, 2024 | 31.68% |
| Mar 31, 2024 | -27.10% |
| Dec 31, 2023 | -47.94% |
| Sep 30, 2023 | -30.46% |
| Jun 30, 2023 | 26.86% |
| Mar 31, 2023 | 18.27% |
| Dec 31, 2022 | -8.47% |
| Sep 30, 2022 | -7.64% |
| Jun 30, 2022 | -28.59% |
| Mar 31, 2022 | -22.33% |
| Dec 31, 2021 | -15.75% |
| Sep 30, 2021 | -17.18% |
| Jun 30, 2021 | -42.01% |